Cargando…
Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins
The lack of antibodies with sufficient cancer selectivity is currently limiting the treatment of solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor-associated antigens that are also found in healthy tissues and often do not display sufficient cancer selectivity to be u...
Autores principales: | Aasted, Mikkel K.M., Groen, Aaron C., Keane, John T., Dabelsteen, Sally, Tan, Edwin, Schnabel, Julia, Liu, Fang, Lewis, Hyeon-Gyu S., Theodoropulos, Constantine, Posey, Avery D., Wandall, Hans H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543972/ https://www.ncbi.nlm.nih.gov/pubmed/37451822 http://dx.doi.org/10.1158/1535-7163.MCT-23-0221 |
Ejemplares similares
-
Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
por: Hollmén, Maija, et al.
Publicado: (2022) -
Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022) -
A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer
por: Chen, Mao-Lin, et al.
Publicado: (2022) -
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021) -
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
por: Zammarchi, Francesca, et al.
Publicado: (2022)